So happy of being part of this new project!! Covering the needs of young oncologists!

Finally launched! 🚀 ¿Te interesa saber más sobre SOLTIyoung? ¿En qué actividades te gustaría participar? ¿Tienes algún proyecto en mente? ¡Comparte tus ideas con nosotros! Te leemos👇Inscríbete hoy mismo en: gruposolti.org/soltiyoung/

Our new article is out, led by Olga Martínez-Sáez! Management of early-stage HER2+ breast cancer and attitudes towards HER2DX in Spain An online questionnaire was conducted by an independent third-party across 70 medical oncologists highly specialized in breast cancer in Spain

Very happy to see that our paper on eBioMedicine – The Lancet Discovery Science is the Editor's pick from the April issue! B-cell immunity is finally gaining its spot in the onocoimmunology field. In this paper we show how it is associated with pCR and prognosis in TNBC ⬇️Aleix Prat #PrecisionOncology EVOMET Fara Brasó Maristany

The new CYCLIBTOOL is here!! Thank you SOLTI #cancerresearch and Meritxell Bellet

Fantastic presentation at #ESMOBreast2024 by Tomás Pascual on biomarker-driven clinical trials in #breastcancer. An exceptional mentor and an even better doctor!

💚💚💚

Amazing talk by Guillermo Villacampa !!!

Great presentation by Benjamin Walbaum, MD and incredible discussion by Sara Tolaney !!

Poster 14P - #ESMOBreast24 Assessing the Predictive Value of #HER2DX pCR-Score for pCR in Early-Stage HER2+ #breastcancer Under Real-World Conditions Olga Martínez-Sáez 👉🏻#HER2DX pCR likelihood score is significantly related to pCR.

Poster 12P - #ESMOBreast24 Updated findings from the first prospective #HER2DX clinical decision impact study on early-stage #HER2+ #breastcancer Olga Martínez-Sáez 👉🏻#HER2DX influenced clinical management in early stages of HER2+, increasing physicians' confidence

Page2, Rodrigo Sánchez-Bayona!

I never imagined how fulfilling this would be. Thrilled to announce that our #DEFINITIVEtrial now has an NCT number: NCT06446882. First SIV this summer! 🔗Link clinicaltrials.gov/study/NCT06446…

🚀 Excited to share our latest publication Nature Communications on Patritumab Deruxtecan (HER3-DXd) in HER2-negative breast cancer! 🎗️ Findings from the SOLTI-1805 TOT-HER3 trial show promising efficacy and identify key genetic markers for early response. Expertly led by Fara Brasó Maristany

Happy to share our published review: Hormone receptor-positive early breast cancer in young women: A comprehensive review - Cancer Treatment Reviews cancertreatmentreviews.com/article/S0305-… Tremendous team effort Isabel Garcia Fructuoso Olga Martínez-Sáez Francesco Schettini, MD PhD 🇮🇹🇪🇸🇪🇺 César y j Sanchez Maria Vidal

Moltes felicitats Aleix!!! 🎉🎉🎉continuem!!💚

Thank you Matteo Lambertini, MD PhD for sharing your knowledge and experience!! Thank you SOLTI #cancerresearch for this opportunity!!

Neoadjuvant ICI therapy is associated with an enhanced pCR rate in patients with early-stage TNBC and PD-L1+ HR+/ERBB2- tumors A Systematic Review and Meta-Analysis 🔗shorturl.at/gst2W #beSOLTI #breastcancer

Tonight, we say farewell to two incredible persons and professionals, Benedetta Conte and Elia Seguí, who have been pivotal to our team's success. Thank you for your hard work and dedication! Your impact will always be appreciated, and we will definitely stay connected as

¡Atención jóvenes oncólogos! ¡Primera beca #SOLTIYoung para asistir al congreso SABCS2024 en San Antonio!✈️ Se cubren inscripción, traslado y manutención. ¡No te pierdas esta oportunidad única!🌍 👉 Abierto a miembros #SOLTIYoung Consulta las bases aquí gruposolti.org/soltiyoung/